Key facts
- It has raised $2.0M; the latest was Seed Round ($2.0M) in Jan 2026.
- Notable investors include UntroD, Inspire Investment (Japan).
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Igualfan
- ·The full record, as it builds
Funding rounds
No funding rounds for Igualfan are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Igualfan
Operator of an IgA antibody research-focused biotechnology company intended to advance human health through immune system enhancement and disease prevention. The company offers innovative IgA antibody-based services that strengthen mucosal immunity, enabling customers to maintain better health, prevent infections and benefit from cutting-edge immunological advancements.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2022
- Website
- igalphan.jp/
- Ownership
- Privately Held (backing)
Igualfan doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Igualfan shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Igualfan in its N-PORT filings yet. We sweep new filings monthly.